

# Ottavio Arancio

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/638880/ottavio-arancio-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

18,005  
citations

63  
h-index

133  
g-index

190  
ext. papers

20,259  
ext. citations

9.2  
avg, IF

6.2  
L-index

#	Paper	IF	Citations
172	Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas. <i>Blood</i> , <b>2021</b> , 138, 2254-2254	2.2	
171	The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders. <i>Journal of Neurochemistry</i> , <b>2021</b> , 159, 958	6	1
170	Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 79, 1813-1829	4.3	1
169	Genetic deletion of $\alpha 7$ nicotinic acetylcholine receptors induces an age-dependent Alzheimer's disease-like pathology. <i>Progress in Neurobiology</i> , <b>2021</b> , 206, 102154	10.9	4
168	Reduced Expression of the PP2A Methyltransferase, PME-1, or the PP2A Methyltransferase, LCMT-1, Alters Sensitivity to Beta-Amyloid-Induced Cognitive and Electrophysiological Impairments in Mice. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 4596-4608	6.6	1
167	Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. <i>Biochemical Pharmacology</i> , <b>2020</b> , 176, 113818	6	24
166	Tau is not necessary for amyloid- $\beta$ -induced synaptic and memory impairments. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 4831-4844	15.9	14
165	What Does the APP Family Do in the Brain?. <i>Neuron</i> , <b>2020</b> , 108, 583-585	13.9	1
164	Involvement of p38 MAPK in Synaptic Function and Dysfunction. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	25
163	Stem Cell Therapy for Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1266, 39-55	3.6	9
162	Neuromodulatory Action of Picomolar Extracellular A $\beta$ 2 Oligomers on Presynaptic and Postsynaptic Mechanisms Underlying Synaptic Function and Memory. <i>Journal of Neuroscience</i> , <b>2019</b> , 39, 5986-6000	6.6	43
161	A Selective and Brain Penetrant p38MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 5298-5311	8.3	14
160	Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 26	19	25
159	Efficient Expression of HIV in Immunocompetent Mouse Brain Reveals a Novel Nonneurotoxic Viral Function in Hippocampal Synaptodendritic Injury and Memory Impairment. <i>MBio</i> , <b>2019</b> , 10,	7.8	11
158	Targeting the NO/cGMP/CREB Phosphorylation Signaling Pathway in Alzheimer's Disease <b>2019</b> ,		1
157	Involvement of SUMO1 in Alzheimer's disease pathology. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2019</b> , 92, 1-P-042	0	
156	Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators. <i>Blood</i> , <b>2019</b> , 134, 4068-4068	2.2	1

155	Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. <i>Autophagy</i> , <b>2019</b> , 15, 113-130	10.2	94
154	Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models. <i>Nature Medicine</i> , <b>2019</b> , 25, 165-175	50.5	279
153	Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 240-251	5.3	14
152	A role for tau in learning, memory and synaptic plasticity. <i>Scientific Reports</i> , <b>2018</b> , 8, 3184	4.9	52
151	Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 37-45	6	22
150	RAGE mediates A $\beta$ accumulation in a mouse model of Alzheimer's disease via modulation of $\beta$ and $\beta$ secretase activity. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 1002-1014	5.6	35
149	The effect of amyloid- $\beta$ peptide on synaptic plasticity and memory is influenced by different isoforms, concentrations, and aggregation status. <i>Neurobiology of Aging</i> , <b>2018</b> , 71, 51-60	5.6	32
148	Role of Amyloid- $\beta$ and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 64, S611-S631	4.3	45
147	Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , <b>2018</b> , 138, 151-159	5.5	19
146	Preparation of Tau Oligomers After the Protein Extraction from Bacteria and Brain Cortices. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1779, 85-97	1.4	1
145	Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 37-37	2.2	1
144	SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model. <i>Neurobiology of Disease</i> , <b>2018</b> , 110, 154-165	7.5	15
143	An isoform-selective p38 $\beta$ mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 70, 86-91	5.6	11
142	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007061	7.6	24
141	Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 46320	4.9	41
140	Amyloid- $\beta$ Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 6926-6937	6.6	38
139	Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. <i>Glia</i> , <b>2017</b> , 65, 1302-1316	9	54
138	Post-translational remodeling of ryanodine receptor induces calcium leak leading to Alzheimer's disease-like pathologies and cognitive deficits. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 749-767	14.3	80

137	Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 8858-8875	8.3	32
136	CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 neurons. <i>Acta Neuropathologica Communications</i> , <b>2017</b> , 5, 77	7.3	73
135	LTP and memory impairment caused by extracellular A $\beta$ and Tau oligomers is APP-dependent. <i>ELife</i> , <b>2017</b> , 6,	8.9	81
134	Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 435	5.3	18
133	Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 59, 743-751	4.3	11
132	Commentary: Analysis of SUMO1-conjugation at synapses. <i>Frontiers in Cellular Neuroscience</i> , <b>2017</b> , 11, 345	6.1	7
131	Mitophagy Failure in Fibroblasts and iPSC-Derived Neurons of Alzheimer's Disease-Associated Presenilin 1 Mutation. <i>Frontiers in Molecular Neuroscience</i> , <b>2017</b> , 10, 291	6.1	62
130	Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. <i>PLoS ONE</i> , <b>2017</b> , 12, e0189413	3.7	8
129	Time Course and Size of Blood-Brain Barrier Opening in a Mouse Model of Blast-Induced Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , <b>2016</b> , 33, 1202-11	5.4	41
128	New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment. <i>European Journal of Medicinal Chemistry</i> , <b>2016</b> , 124, 82-102	6.8	27
127	Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. <i>Aging Cell</i> , <b>2016</b> , 15, 914-23	9.9	26
126	A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 35	19	22
125	Molecular Mechanisms of Learning and Memory <b>2016</b> , 1-27		4
124	PP2A methylation controls sensitivity and resistance to $\beta$ amyloid-induced cognitive and electrophysiological impairments. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 3347-52	11.5	34
123	Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 49, 707-21	4.3	20
122	PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 295-302	4.3	26
121	Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric A $\beta$ 2: an early index of Alzheimer's disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 32553	4.9	35
120	Connectivity and circuitry in a dish versus in a brain. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 44	9	11

119	Rodent models for Alzheimer's disease drug discovery. <i>Expert Opinion on Drug Discovery</i> , <b>2015</b> , 10, 703-16.	16.2	129
118	Increased neuronal PreP activity reduces A $\beta$ accumulation, attenuates neuroinflammation and improves mitochondrial and synaptic function in Alzheimer disease's mouse model. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5198-210	5.6	58
117	Characterization of a subpopulation of developing cortical interneurons from human iPSCs within serum-free embryoid bodies. <i>American Journal of Physiology - Cell Physiology</i> , <b>2015</b> , 308, C209-19	5.4	13
116	SUMO1 Affects Synaptic Function, Spine Density and Memory. <i>Scientific Reports</i> , <b>2015</b> , 5, 10730	4.9	42
115	Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia. <i>BMC Neuroscience</i> , <b>2015</b> , 16, 67	3.2	12
114	Network compensation of cyclic GMP-dependent protein kinase II knockout in the hippocampus by Ca <sup>2+</sup> -permeable AMPA receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 3122-7	11.5	30
113	Targeting human central nervous system protein kinases: An isoform selective p38MAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. <i>ACS Chemical Neuroscience</i> , <b>2015</b> , 6, 666-80	5.7	52
112	Synaptic therapy in Alzheimer's disease: a CREB-centric approach. <i>Neurotherapeutics</i> , <b>2015</b> , 12, 29-41	6.4	89
111	SUMO modulation of protein aggregation and degradation. <i>AIMS Molecular Science</i> , <b>2015</b> , 2, 382-410	0.9	8
110	Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. <i>Biochemical Pharmacology</i> , <b>2014</b> , 88, 450-67	6	119
109	Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. <i>Neuron</i> , <b>2014</b> , 83, 1131-43	13.9	616
108	A novel mechanism for cyclic adenosine monophosphate-mediated memory formation: Role of amyloid beta. <i>Annals of Neurology</i> , <b>2014</b> , 75, 602-7	9.4	21
107	The schizophrenia susceptibility gene DTNBP1 modulates AMPAR synaptic transmission and plasticity in the hippocampus of juvenile DBA/2J mice. <i>Molecular and Cellular Neurosciences</i> , <b>2014</b> , 58, 76-84	4.8	18
106	Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 520-31	5.6	66
105	Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease. <i>Scientific Reports</i> , <b>2014</b> , 4, 7190	4.9	58
104	Loss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits. <i>Neuron</i> , <b>2014</b> , 83, 1482	13.9	14
103	Picomolar amyloid- $\beta$ peptides enhance spontaneous astrocyte calcium transients. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 38, 49-62	4.3	43
102	Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. <i>Scientific Reports</i> , <b>2014</b> , 4, 6352	4.9	34

101	Characterization and molecular profiling of PSEN1 familial Alzheimer's disease iPSC-derived neural progenitors. <i>PLoS ONE</i> , <b>2014</b> , 9, e84547	3.7	120
100	A time course analysis of the electrophysiological properties of neurons differentiated from human induced pluripotent stem cells (iPSCs). <i>PLoS ONE</i> , <b>2014</b> , 9, e103418	3.7	77
99	Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. <i>PLoS ONE</i> , <b>2014</b> , 9, e111899	3.7	115
98	Electrophysiological profiles of induced neurons converted directly from adult human fibroblasts indicate incomplete neuronal conversion. <i>Cellular Reprogramming</i> , <b>2014</b> , 16, 439-46	2.1	8
97	A $\beta$ -42 monomers or oligomers have different effects on autophagy and apoptosis. <i>Autophagy</i> , <b>2014</b> , 10, 1827-43	10.2	52
96	RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 8749-60	6.6	39
95	Glut4 expression defines an insulin-sensitive hypothalamic neuronal population. <i>Molecular Metabolism</i> , <b>2014</b> , 3, 452-9	8.8	26
94	Dynamin 1 is required for memory formation. <i>PLoS ONE</i> , <b>2014</b> , 9, e91954	3.7	23
93	Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. <i>PLoS ONE</i> , <b>2014</b> , 9, e111898	3.7	89
92	Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 6054-68	8.3	24
91	SUMO and Alzheimer's disease. <i>NeuroMolecular Medicine</i> , <b>2013</b> , 15, 720-36	4.6	56
90	Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , <b>2013</b> , 60, 285-94	6.8	73
89	Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1). <i>Mammalian Genome</i> , <b>2013</b> , 24, 30-43	3.2	12
88	Amyloid- $\beta$ peptide: Dr. Jekyll or Mr. Hyde?. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33 Suppl 1, S111-20	4.3	78
87	Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 2052-63	5.6	87
86	Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. <i>Nature Communications</i> , <b>2013</b> , 4, 1939	17.4	60
85	Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. <i>PLoS ONE</i> , <b>2013</b> , 8, e66226	3.7	49
84	A reliable way to detect endogenous murine $\beta$ amyloid. <i>PLoS ONE</i> , <b>2013</b> , 8, e55647	3.7	29

83	An intracellular threonine of amyloid- $\beta$ precursor protein mediates synaptic plasticity deficits and memory loss. <i>PLoS ONE</i> , <b>2013</b> , 8, e57120	3.7	16
82	Role of leaky neuronal ryanodine receptors in stress-induced cognitive dysfunction. <i>Cell</i> , <b>2012</b> , 150, 1055-62	5.7	100
81	Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 6784-801	8.3	20
80	FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. <i>Cell</i> , <b>2012</b> , 149, 1314-26	56.2	139
79	Reduction of synaptojanin 1 ameliorates synaptic and behavioral impairments in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 15271-6	6.6	53
78	Caspase-9 mediates synaptic plasticity and memory deficits of Danish dementia knock-in mice: caspase-9 inhibition provides therapeutic protection. <i>Molecular Neurodegeneration</i> , <b>2012</b> , 7, 60	19	13
77	But not $\beta$ secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. <i>EMBO Molecular Medicine</i> , <b>2012</b> , 4, 171-9	12	103
76	Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation. <i>Hippocampus</i> , <b>2012</b> , 22, 1027-39	3.5	16
75	Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 3076-87	8.3	60
74	Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?. <i>Biochemical Journal</i> , <b>2012</b> , 446, 165-77	3.8	75
73	5-HT $\alpha$ receptor stimulation leads to soluble APP $\beta$ production through MMP-9 upregulation. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 32, 437-45	4.3	14
72	Inhibition of amyloid-beta (A $\beta$ ) peptide-binding alcohol dehydrogenase-A $\beta$ interaction reduces A $\beta$ accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 2313-20	6.6	139
71	A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons. <i>Experimental Neurology</i> , <b>2011</b> , 229, 409-20	5.7	26
70	APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant. <i>EMBO Journal</i> , <b>2011</b> , 30, 2501-9	13	42
69	Endogenous amyloid- $\beta$ s necessary for hippocampal synaptic plasticity and memory. <i>Annals of Neurology</i> , <b>2011</b> , 69, 819-30	9.4	200
68	Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 20822-7	11.5	50
67	Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 11414-25	6.6	78
66	Memory deficits due to familial British dementia BRI2 mutation are caused by loss of BRI2 function rather than amyloidosis. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 14915-24	6.6	44

65	Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 16419-28	6.6	140
64	The ankyrin repeat-rich membrane spanning (ARMS)/Kidins220 scaffold protein is regulated by activity-dependent calpain proteolysis and modulates synaptic plasticity. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 40472-8	5.4	16
63	Preparation of oligomeric beta-amyloid 1-42 and induction of synaptic plasticity impairment on hippocampal slices. <i>Journal of Visualized Experiments</i> , <b>2010</b> ,	1.6	33
62	The ARMS/Kidins220 scaffold protein modulates synaptic transmission. <i>Molecular and Cellular Neurosciences</i> , <b>2010</b> , 45, 92-100	4.8	27
61	Reversal of long-term dendritic spine alterations in Alzheimer disease models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 16877-82	11.5	181
60	Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 8075-86	6.6	242
59	Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 2305-22	8.7	65
58	Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 18, 131-9	4.3	218
57	A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. <i>BMC Pharmacology</i> , <b>2009</b> , 9, S44		1
56	Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J. <i>Neurobiology of Aging</i> , <b>2009</b> , 30, 257-65	5.6	30
55	MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. <i>Expert Review of Neurotherapeutics</i> , <b>2009</b> , 9, 1635-45	4.3	48
54	Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2009</b> , 9, 448-62	3.2	51
53	Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 17, 59-68	4.3	41
52	Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. <i>Nature Medicine</i> , <b>2008</b> , 14, 1097-105	50.5	707
51	Oligomeric amyloid-beta peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. <i>Nature Neuroscience</i> , <b>2008</b> , 11, 547-54	25.5	156
50	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. <i>Neurobiology of Disease</i> , <b>2008</b> , 31, 46-57	7.5	84
49	Isolation and characterization of "Reprotoxin", a novel protein complex from Daboia russelii snake venom. <i>Biochimie</i> , <b>2008</b> , 90, 1545-59	4.6	26
48	Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. <i>Journal of Neurochemistry</i> , <b>2008</b> , 107, 1001-13	6	83



47	Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 14537-45	6.6	533
46	Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 3521-30	6.6	169
45	A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. <i>Channels</i> , <b>2008</b> , 2, 230-2	3	14
44	Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 9415-20	11.5	133
43	A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2008</b> , 325, 146-53	4.7	190
42	Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 7327-32	11.5	200
41	Role of phosphodiesterase 5 in synaptic plasticity and memory. <i>Neuropsychiatric Disease and Treatment</i> , <b>2008</b> , 4, 371-87	3.1	68
40	Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. <i>PLoS ONE</i> , <b>2008</b> , 3, e3604	3.7	100
39	Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 2796-807	15.9	160
38	PIP2: a new key player in Alzheimer's disease. <i>Cellscience</i> , <b>2008</b> , 5, 44-47		10
37	Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII. <i>European Journal of Neuroscience</i> , <b>2007</b> , 25, 3583-96	3.5	27
36	Neurotrophins, synaptic plasticity and dementia. <i>Current Opinion in Neurobiology</i> , <b>2007</b> , 17, 325-30	7.6	142
35	RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. <i>Current Molecular Medicine</i> , <b>2007</b> , 7, 735-42	2.5	123
34	Oligomers of beta-amyloid peptide inhibit BDNF-induced arc expression in cultured cortical Neurons. <i>Current Alzheimer Research</i> , <b>2007</b> , 4, 518-21	3	24
33	A GluR1-cGKII interaction regulates AMPA receptor trafficking. <i>Neuron</i> , <b>2007</b> , 56, 670-88	13.9	151
32	Fibrillar beta-amyloid impairs the late phase of long term potentiation. <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 179-83	3	22
31	Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , <b>2006</b> , 17, 497-523	4.7	42
30	Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. <i>Journal of Neuroscience</i> , <b>2006</b> , 26, 319-27	6.6	417

29	Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. <i>Cell</i> , <b>2006</b> , 126, 775-88	56.2	338
28	Estimation of the mean from sums with unknown numbers of summands. <i>Biometrics</i> , <b>2006</b> , 62, 918-20	1.8	2
27	BDNF-mediated neurotransmission relies upon a myosin VI motor complex. <i>Nature Neuroscience</i> , <b>2006</b> , 9, 1009-18	25.5	109
26	Early presynaptic changes during plasticity in cultured hippocampal neurons. <i>EMBO Journal</i> , <b>2006</b> , 25, 4361-71	13	19
25	ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. <i>FASEB Journal</i> , <b>2005</b> , 19, 597-8	0.9	192
24	Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2005</b> , 2, 137-40	3	21
23	Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 6887-97	6.6	196
22	RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. <i>EMBO Journal</i> , <b>2004</b> , 23, 4096-105	13	274
21	alpha-Synuclein produces a long-lasting increase in neurotransmitter release. <i>EMBO Journal</i> , <b>2004</b> , 23, 4506-16	13	151
20	Cell cultures from animal models of Alzheimer's disease as a tool for faster screening and testing of drug efficacy. <i>Journal of Molecular Neuroscience</i> , <b>2004</b> , 24, 15-21	3.3	13
19	ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. <i>Science</i> , <b>2004</b> , 304, 448-52	33.3	1008
18	Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. <i>Annals of Neurology</i> , <b>2004</b> , 55, 801-14	9.4	280
17	Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. <i>American Journal of Pathology</i> , <b>2004</b> , 165, 795-805	5.8	112
16	Presynaptic CaMKII is necessary for synaptic plasticity in cultured hippocampal neurons. <i>Neuron</i> , <b>2004</b> , 42, 129-41	13.9	105
15	Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 1624-34	15.9	330
14	Calpain inhibitors, a treatment for Alzheimer's disease: position paper. <i>Journal of Molecular Neuroscience</i> , <b>2003</b> , 20, 357-62	3.3	52
13	Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. <i>Neurochemical Research</i> , <b>2003</b> , 28, 1009-15	4.6	14
12	Receptor protein tyrosine phosphatase alpha is essential for hippocampal neuronal migration and long-term potentiation. <i>EMBO Journal</i> , <b>2003</b> , 22, 4121-31	13	67

11	Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. <i>Science</i> , <b>2003</b> , 301, 805-9	33.3	3427
10	Calpain inhibitors: a treatment for Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , <b>2002</b> , 19, 135-43	3.3	47
9	Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 13217-21	11.5	426
8	Rapid increase in clusters of presynaptic proteins at onset of long-lasting potentiation. <i>Science</i> , <b>2001</b> , 294, 1547-50	33.3	147
7	Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 143-9	6.6	148
6	Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. <i>Progress in Brain Research</i> , <b>1998</b> , 118, 155-72	2.9	218
5	The Specific Role of cGMP in Hippocampal LTP. <i>Learning and Memory</i> , <b>1998</b> , 5, 231-245	2.8	60
4	Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. <i>Cell</i> , <b>1996</b> , 87, 1025-35	56.2	339
3	Fibrillatory activity and other membrane changes in partially denervated muscles. <i>Muscle and Nerve</i> , <b>1989</b> , 12, 149-53	3.4	13
2	Transitory L-carnitine depletion in rat skeletal muscle by D-carnitine. <i>Pharmacological Research</i> , <b>1989</b> , 21, 163-8	10.2	2
1	ECSIT prevents Alzheimer's disease pathology by regulating neuronal mitochondrial ROS and mitophagy		1